<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03572478</url>
  </required_header>
  <id_info>
    <org_study_id>IRB18-0154</org_study_id>
    <nct_id>NCT03572478</nct_id>
  </id_info>
  <brief_title>Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer</brief_title>
  <official_title>A Phase Ib/IIa Study of Rucaparib (PARP Inhibitor) Combined With Nivolumab in Metastatic Castrate - Resistant Prostate Cancer and Advanced/Recurrent Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clovis Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1/phase 2a study of the combination of immune checkpoint inhibitor&#xD;
      (nivolumab) in combination with the PARP inhibitor (rucaparib) for patients with metastatic&#xD;
      castration resistant prostate cancer (mCRPC) and metastatic/recurrent endometrial cancer.&#xD;
&#xD;
      In the phase 1 portion, the safety of the combination dosing will be determined. If the&#xD;
      combination dosing is determined to be safe and feasible, the study will move onto phase 2a.&#xD;
&#xD;
      In the phase 2a portion, participants will be randomized to receive either: rucaparib alone,&#xD;
      nivolumab alone, or combination therapy (rucaparib and nivolumab).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated due to lack of efficacy.&#xD;
  </why_stopped>
  <start_date type="Actual">August 14, 2018</start_date>
  <completion_date type="Actual">October 1, 2020</completion_date>
  <primary_completion_date type="Actual">February 29, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Dose Limiting Toxicities (DLT) (Phase 1)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Dose limiting toxicities (DLT) is measured by patients with grade 3 or 4 toxicity within 4 weeks of starting leading to discontinuation of rucaparib for at least 1 week</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Patients With T Cell Inflammation in the Tumor Compared Between Treatment Arms (Phase 2)</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Disease Progression in Prostate Cancer Patients (Phase 2)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Disease Progression in Endometrial Cancer Patients (Phase 2)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate in Prostate Cancer Patients (Phase 2)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate in Endometrial Cancer Patients (Phase 2)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Number of T Cells in Tumor Samples Compared Between Treatment Arms (Phase 2)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of Change in T Cells in Tumor Samples and PTEN Mutation Status (Phase 2)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>Combination Therapy (Phase 1b Cohort)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive rucaparib plus nivolumab in 4 week cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rucaparib (Phase 2b Randomized Cohort)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive rucaparib alone in 4 week cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivolumab (Phase 2b Randomized Cohort)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive nivolumab alone in 4 week cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Therapy (Phase 2b Randomized Cohort)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive rucaparib plus nivolumab in 4 week cycles. Participants will receive rucaparib alone in cycle 1 and begin nivolumab on day 1 of Cycle 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rucaparib</intervention_name>
    <description>600 mg taken by mouth twice daily.</description>
    <arm_group_label>Combination Therapy (Phase 1b Cohort)</arm_group_label>
    <arm_group_label>Combination Therapy (Phase 2b Randomized Cohort)</arm_group_label>
    <arm_group_label>Rucaparib (Phase 2b Randomized Cohort)</arm_group_label>
    <other_name>Rubraca(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>480 mg given by intravenous (IV) infusion every 4 weeks.</description>
    <arm_group_label>Combination Therapy (Phase 1b Cohort)</arm_group_label>
    <arm_group_label>Combination Therapy (Phase 2b Randomized Cohort)</arm_group_label>
    <arm_group_label>Nivolumab (Phase 2b Randomized Cohort)</arm_group_label>
    <other_name>Opdivo(R)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have the ability to understand and the willingness to signed a written&#xD;
             informed consent document.&#xD;
&#xD;
          -  Patients must have histologically or cytologically confirmed CRPC or endometrial&#xD;
             cancer that is metastatic. Evidence of disease progression on a prior therapy is not&#xD;
             required.&#xD;
&#xD;
          -  Patients must have at least one lesion that is amenable to biopsy and the treating&#xD;
             physician must deem this safe.&#xD;
&#xD;
          -  Patient must be willing to undergo two mandatory research-only biopsies.&#xD;
&#xD;
          -  Prostate cancer patients:&#xD;
&#xD;
               -  Patients must be surgically or medically castrated, with serum testosterone&#xD;
                  levels ≤ 50 ng/mL Patients being treated with Gonadotropin-releasing hormone&#xD;
                  (GnRH) agonists must have such therapy continued throughout the study.&#xD;
&#xD;
               -  Patients should have received at least one androgen receptor (AR)-targeted&#xD;
                  therapy with abiraterone acetate or enzalutamide. Multiple lines of prior&#xD;
                  AR-targeted therapy and chemotherapy are permitted. A washout of two weeks from&#xD;
                  prior endocrine therapy (other than GnRH agonist); four weeks washout period from&#xD;
                  prior cytotoxic chemotherapy or other anticancer agents is required (prior to day&#xD;
                  1 of study therapy); six weeks washout period to allow for anti-androgen&#xD;
                  withdrawal for patients managed with antiandrogen therapy such as bicalutamide.&#xD;
&#xD;
          -  Endometrial cancer patients:&#xD;
&#xD;
               -  An unlimited number of prior hormonal and/or chemotherapy regimens are permitted.&#xD;
                  A washout of two weeks from prior endocrine therapy (other than GnRH agonist) and&#xD;
                  four weeks from prior cytotoxic chemotherapy or other anticancer agents is&#xD;
                  required (prior to day 1 of study therapy).&#xD;
&#xD;
          -  At least 5 days should have elapsed since any non-study related minor surgical&#xD;
             procedure and at least 21 days since any major surgical procedure prior to the first&#xD;
             dose of rucaparib and the first dose of nivolumab.&#xD;
&#xD;
          -  Must have an ability to swallow pills or capsules. Patients should have no current&#xD;
             clinical evidence of bowel obstruction.&#xD;
&#xD;
          -  Age must be ≥ 18 years.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status must be ≤ 1&#xD;
&#xD;
          -  Patients must have normal hepatic, renal and marrow function as defined below:&#xD;
&#xD;
               -  hemoglobin &gt; 10 g/dL&#xD;
&#xD;
               -  leukocytes ≥ 3,000/mcL&#xD;
&#xD;
               -  absolute neutrophil count ≥ 1,500/mcL&#xD;
&#xD;
               -  platelets ≥ 150,000/mcL&#xD;
&#xD;
               -  total bilirubin within normal institutional limits&#xD;
&#xD;
               -  alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 1.5 ×&#xD;
                  institutional upper limit of normal&#xD;
&#xD;
               -  creatinine within normal institutional limits OR creatinine clearance ≥ 60&#xD;
                  mL/min/1.73 m2 for patients with creatinine levels above institutional normal.&#xD;
&#xD;
          -  Prior palliative radiotherapy must have been completed at least 2 weeks prior to first&#xD;
             dose of study drug. Subjects with symptomatic tumor lesions at baseline that may&#xD;
             require palliative radiotherapy within 4 weeks of first dose of study drug are&#xD;
             strongly encouraged to receive palliative radiotherapy prior to enrollment.&#xD;
&#xD;
          -  Reproductive Status: Rucaparib caused post-implantation loss (100% early resorptions)&#xD;
             at all doses administered in an embryo-fetal development study. Based on its mechanism&#xD;
             of action, nivolumab can cause fetal harm when administered to a pregnant woman.&#xD;
             Pregnant women are therefore not eligible for this study.&#xD;
&#xD;
               -  Women of child-bearing potential (WOCBP) must have a negative serum pregnancy&#xD;
                  test result less than 3 days prior to administration of the first dose of&#xD;
                  rucaparib.&#xD;
&#xD;
               -  WOCBP must not be considering getting pregnant during the study.&#xD;
&#xD;
               -  WOCBP and their male partners must agree to use a highly effective, reliable form&#xD;
                  of contraception during treatment; for 6 months following the last dose of&#xD;
                  rucaparib; and for at least 5 months following the last dose of nivolumab.&#xD;
&#xD;
               -  Men who are sexually active with WOCBP must agree to use a highly effective,&#xD;
                  reliable form of contraception during treatment; 6 months following the last dose&#xD;
                  of rucaparib; and for a period of 7 months after the last dose of nivolumab .&#xD;
&#xD;
               -  In addition to the above methods of contraception, use of a condom by male&#xD;
                  patients is recommended to prevent transfer of drug through semen.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with active, known, or suspected autoimmune disease. Subjects with vitiligo,&#xD;
             type I diabetes, mellitus, residual hypothyroidism due to autoimmune condition only&#xD;
             requiring hormone replacement, psoriasis not requiring systemic treatment, childhood&#xD;
             asthma that is not currently active, or conditions not expected to recur in the&#xD;
             absence of an external trigger are permitted to enroll.&#xD;
&#xD;
          -  Patients with a condition requiring systemic treatment with either corticosteroids (&gt;&#xD;
             10 mg daily prednisone equivalents) or other immunosuppressive medications within 14&#xD;
             days of study drug administration except for adrenal replacement steroid doses &gt; 10 mg&#xD;
             daily prednisone equivalent in the absence of active autoimmune disease. Note:&#xD;
             Treatment with a short course of steroids (&lt; 5 days) up to 7 days prior to initiating&#xD;
             study drug is permitted.&#xD;
&#xD;
          -  Patients who are receiving any other investigational agents.&#xD;
&#xD;
          -  Prior exposure to PD-1 or PD-L1 inhibitors, other immune checkpoint inhibitors (e.g.&#xD;
             anti-LAG-3, and anti-CTLA-4 antibodies), or PARP inhibitors.&#xD;
&#xD;
          -  Patients with a &quot;currently active&quot; second invasive malignancy other than non-melanoma&#xD;
             skin cancers. Patients are not considered to have a &quot;currently active&quot; malignancy if&#xD;
             they have completed therapy and have been free of disease for ≥ 1 years.&#xD;
&#xD;
          -  Patients with known and untreated or progressing brain metastases are excluded from&#xD;
             this clinical trial because of their poor prognosis and because they often develop&#xD;
             progressive neurologic dysfunction that would confound the evaluation of neurologic&#xD;
             and other adverse events. Patients whose brain metastases have been treated with&#xD;
             surgery and/or radiotherapy and are without evidence of progression on scan for at&#xD;
             least 4 weeks, and are off steroids or antiseizure medications, will be eligible .&#xD;
&#xD;
          -  Patients with symptomatic or impending spinal cord compression are not eligible unless&#xD;
             appropriately treated.&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to nivolumab or rucaparib.&#xD;
&#xD;
          -  Based on in vitro CYP interaction studies, caution should be used for concomitant&#xD;
             medications with a narrow therapeutic window that are substrates of CYP2C19, CYP2C9,&#xD;
             and/or CYP3A. Selection of an alternate concomitant medication is recommended. Caution&#xD;
             should also be exercised for concomitant use of certain statin drugs (e.g.&#xD;
             rosuvastatin and fluvastatin) due to potential increase in exposure from inhibition of&#xD;
             BCRP and CYP2C9. An updated list of clinically relevant P450 drug interactions (e.g:&#xD;
             Flockhart Table http://medicine.iupui.edu/clinpharm/ddis/main-table/) should be&#xD;
             reviewed while screening patients for study.&#xD;
&#xD;
               -  Patients taking warfarin should have international normalized ration (INR)&#xD;
                  monitored regularly according to standard institutional practices&#xD;
&#xD;
               -  Because rucaparib is a moderate inhibitor of P-gp in vitro, caution should be&#xD;
                  exercised for patients receiving rucaparib and requiring concomitant medication&#xD;
                  with digoxin. Patients taking digoxin should have their digoxin levels monitored&#xD;
                  after starting rucaparib and then regularly per standard clinical practice.&#xD;
&#xD;
          -  Patients on parenteral nutrition are not eligible. Patients must not have a&#xD;
             pre-existing duodenal stent or any gastrointestinal disorder or defect that would, in&#xD;
             the opinion of the treating investigator, interfere with absorption of rucaparib.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, requirement for&#xD;
             oxygen therapy, ongoing or active infection other than minor urinary tract infection,&#xD;
             symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or&#xD;
             psychiatric illness/social situations that would limit compliance with study&#xD;
             requirements.&#xD;
&#xD;
          -  Known history of chronic hepatitis B or C as evidenced by:&#xD;
&#xD;
               -  Positive test for hepatitis B surface antigen&#xD;
&#xD;
               -  Positive test for qualitative hepatitis C viral load (by polymerase chain&#xD;
                  reaction [PCR])&#xD;
&#xD;
               -  Note: Subjects with positive hepatitis C antibody and negative quantitative&#xD;
                  hepatitis C by polymerase chain reaction (PCR) are eligible.&#xD;
&#xD;
          -  Human Immunodeficiency Virus (HIV)-positive patients on combination antiretroviral&#xD;
             therapy are ineligible because of the potential for pharmacokinetic interactions with&#xD;
             rucaparib. In addition, these patients are at increased risk of lethal infections when&#xD;
             treated with marrow-suppressive therapy.&#xD;
&#xD;
          -  Prior organ allograft or allogeneic bone marrow transplantation.&#xD;
&#xD;
          -  Adverse effect of prior therapy not improved to Common Terminology Criteria for&#xD;
             Adverse Events (CTCAE) Grade 1 or below with the exception of alopecia or lymphopenia.&#xD;
             Ongoing Grade 2 non-hematologic toxicity (e.g. neuropathy) related to most recent&#xD;
             treatment regimen may be permitted with prior advanced approval from the Lead&#xD;
             Principal Investigator.&#xD;
&#xD;
          -  Initiated denosumab or bisphosphonate therapy or adjusted denosumab or bisphosphonate&#xD;
             dose/regimen within 4 weeks prior to first dose of rucaparib. Patients on a stable&#xD;
             denosumab or bisphosphonate regimen are eligible and may continue treatment.&#xD;
&#xD;
          -  Evidence or history of active or latent tuberculosis infection including purified&#xD;
             protein derivative (PPD) recently converted to positive.&#xD;
&#xD;
          -  Use of non-oncology vaccines containing live virus for prevention of infectious&#xD;
             diseases within 12 weeks prior to study drug. The use of inactivated seasonal&#xD;
             influenza vaccines, e.g., Fluzone®, will be permitted on study without restriction.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter Stadler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 19, 2018</study_first_submitted>
  <study_first_submitted_qc>June 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2018</study_first_posted>
  <results_first_submitted>January 26, 2021</results_first_submitted>
  <results_first_submitted_qc>January 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 12, 2021</results_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Rucaparib</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 1, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT03572478/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The study was terminated due to lack of efficacy such that participants were enrolled only in phase 1 cohort (single arm).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Combination Therapy (Phase 1 Cohort)</title>
          <description>Although we initially planned to conduct phase 1/2a study in the protocol, participants were enrolled only in phase 1 cohort.&#xD;
Participants will receive rucaparib plus nivolumab in 4 week cycles.&#xD;
Rucaparib: 600 mg taken by mouth twice daily.&#xD;
Nivolumab: 480 mg given by intravenous (IV) infusion every 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Combination Therapy (Phase 1 Cohort)</title>
          <description>Although we initially planned to conduct phase 1/2a study in the protocol, participants were enrolled only in phase 1 cohort.&#xD;
Participants will receive rucaparib plus nivolumab in 4 week cycles.&#xD;
Rucaparib: 600 mg taken by mouth twice daily.&#xD;
Nivolumab: 480 mg given by intravenous (IV) infusion every 4 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72" lower_limit="60" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Dose Limiting Toxicities (DLT) (Phase 1)</title>
        <description>Dose limiting toxicities (DLT) is measured by patients with grade 3 or 4 toxicity within 4 weeks of starting leading to discontinuation of rucaparib for at least 1 week</description>
        <time_frame>8 weeks</time_frame>
        <population>Two patients were not evaluable for DLT due to rapidly progressive disease.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy (Phase 1 Cohort)</title>
            <description>Although we initially planned to conduct phase 1/2a study in the protocol, participants were enrolled only in phase 1 cohort.&#xD;
Participants will receive rucaparib plus nivolumab in 4 week cycles.&#xD;
Rucaparib: 600 mg taken by mouth twice daily.&#xD;
Nivolumab: 480 mg given by intravenous (IV) infusion every 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Dose Limiting Toxicities (DLT) (Phase 1)</title>
          <description>Dose limiting toxicities (DLT) is measured by patients with grade 3 or 4 toxicity within 4 weeks of starting leading to discontinuation of rucaparib for at least 1 week</description>
          <population>Two patients were not evaluable for DLT due to rapidly progressive disease.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Patients With T Cell Inflammation in the Tumor Compared Between Treatment Arms (Phase 2)</title>
        <time_frame>4 weeks</time_frame>
        <population>No participants were enrolled in Phase 2 cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy (Phase 1 Cohort)</title>
            <description>Although we initially planned to conduct phase 1/2a study in the protocol, participants were enrolled only in phase 1 cohort.&#xD;
Participants will receive rucaparib plus nivolumab in 4 week cycles.&#xD;
Rucaparib: 600 mg taken by mouth twice daily.&#xD;
Nivolumab: 480 mg given by intravenous (IV) infusion every 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Patients With T Cell Inflammation in the Tumor Compared Between Treatment Arms (Phase 2)</title>
          <population>No participants were enrolled in Phase 2 cohort.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Disease Progression in Prostate Cancer Patients (Phase 2)</title>
        <time_frame>24 months</time_frame>
        <population>No participants were enrolled in Phase 2 cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy (Phase 1 Cohort)</title>
            <description>Although we initially planned to conduct phase 1/2a study in the protocol, participants were enrolled only in phase 1 cohort.&#xD;
Participants will receive rucaparib plus nivolumab in 4 week cycles.&#xD;
Rucaparib: 600 mg taken by mouth twice daily.&#xD;
Nivolumab: 480 mg given by intravenous (IV) infusion every 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Disease Progression in Prostate Cancer Patients (Phase 2)</title>
          <population>No participants were enrolled in Phase 2 cohort.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Disease Progression in Endometrial Cancer Patients (Phase 2)</title>
        <time_frame>24 months</time_frame>
        <population>No participants were enrolled in Phase 2 cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy (Phase 1 Cohort)</title>
            <description>Although we initially planned to conduct phase 1/2a study in the protocol, participants were enrolled only in phase 1 cohort.&#xD;
Participants will receive rucaparib plus nivolumab in 4 week cycles.&#xD;
Rucaparib: 600 mg taken by mouth twice daily.&#xD;
Nivolumab: 480 mg given by intravenous (IV) infusion every 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Disease Progression in Endometrial Cancer Patients (Phase 2)</title>
          <population>No participants were enrolled in Phase 2 cohort.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate in Prostate Cancer Patients (Phase 2)</title>
        <time_frame>24 months</time_frame>
        <population>No participants were enrolled in Phase 2 cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy (Phase 1 Cohort)</title>
            <description>Although we initially planned to conduct phase 1/2a study in the protocol, participants were enrolled only in phase 1 cohort.&#xD;
Participants will receive rucaparib plus nivolumab in 4 week cycles.&#xD;
Rucaparib: 600 mg taken by mouth twice daily.&#xD;
Nivolumab: 480 mg given by intravenous (IV) infusion every 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate in Prostate Cancer Patients (Phase 2)</title>
          <population>No participants were enrolled in Phase 2 cohort.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate in Endometrial Cancer Patients (Phase 2)</title>
        <time_frame>24 months</time_frame>
        <population>No participants were enrolled in Phase 2 cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy (Phase 1 Cohort)</title>
            <description>Although we initially planned to conduct phase 1/2a study in the protocol, participants were enrolled only in phase 1 cohort.&#xD;
Participants will receive rucaparib plus nivolumab in 4 week cycles.&#xD;
Rucaparib: 600 mg taken by mouth twice daily.&#xD;
Nivolumab: 480 mg given by intravenous (IV) infusion every 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate in Endometrial Cancer Patients (Phase 2)</title>
          <population>No participants were enrolled in Phase 2 cohort.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Number of T Cells in Tumor Samples Compared Between Treatment Arms (Phase 2)</title>
        <time_frame>4 weeks</time_frame>
        <population>No participants were enrolled in Phase 2 cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy (Phase 1 Cohort)</title>
            <description>Although we initially planned to conduct phase 1/2a study in the protocol, participants were enrolled only in phase 1 cohort.&#xD;
Participants will receive rucaparib plus nivolumab in 4 week cycles.&#xD;
Rucaparib: 600 mg taken by mouth twice daily.&#xD;
Nivolumab: 480 mg given by intravenous (IV) infusion every 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Number of T Cells in Tumor Samples Compared Between Treatment Arms (Phase 2)</title>
          <population>No participants were enrolled in Phase 2 cohort.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation of Change in T Cells in Tumor Samples and PTEN Mutation Status (Phase 2)</title>
        <time_frame>4 weeks</time_frame>
        <population>No participants were enrolled in Phase 2 cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy (Phase 1 Cohort)</title>
            <description>Although we initially planned to conduct phase 1/2a study in the protocol, participants were enrolled only in phase 1 cohort.&#xD;
Participants will receive rucaparib plus nivolumab in 4 week cycles.&#xD;
Rucaparib: 600 mg taken by mouth twice daily.&#xD;
Nivolumab: 480 mg given by intravenous (IV) infusion every 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of Change in T Cells in Tumor Samples and PTEN Mutation Status (Phase 2)</title>
          <population>No participants were enrolled in Phase 2 cohort.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected up to 28 days after the end of treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Combination Therapy (Phase 1 Cohort)</title>
          <description>Although we initially planned to conduct phase 1/2a study in the protocol, participants were enrolled only in phase 1 cohort.&#xD;
Participants will receive rucaparib plus nivolumab in 4 week cycles.&#xD;
Rucaparib: 600 mg taken by mouth twice daily.&#xD;
Nivolumab: 480 mg given by intravenous (IV) infusion every 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>neoplasms benign, malignant and unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Esophageal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Lymphocyte count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Walter STadler</name_or_title>
      <organization>University of Chicago</organization>
      <phone>773-702-4150</phone>
      <email>wstadler@medicine.bsd.uchicago.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

